Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib plus adalimumab vs baricitinib alone in refractory rheumatoid arthritis
2020-004345-37Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Feb 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Refractory rheumatoid arthritis (RRA) comparing Combination therapy: adalimumab + baricitinib with Monotherapy: baricitinib conventional therapy (2 arms). Started Feb 2021; status: active.
02
Drugs
baricitinibadalimumab
03
Conditions
Refractory rheumatoid arthritis (RRA)
Beyond the preview
Go deeper on 2020-004345-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004345-37.